COX-2 Sales Reps Remain "Extraordinarily Busy" At Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
Celebrex and Bextra had strong fourth quarter sales despite Merck's withdrawal of Vioxx, CEO McKinnell says. Pfizer will hold off on deciding whether to restructure its COX-2 inhibitor team until after an FDA advisory committee review next month.
You may also be interested in...
COX-2 Inhibitor Meeting Expands To Three Days; GI/Cardiac Safety On Agenda
FDA advisory committees will consider overall benefit-risk of COX-2s and related products, both gastrointestinal safety and cardiovascular effects. The meeting will be held Feb. 16-18.
Pfizer Celebrex Sales Reps Will Discuss Alternate Therapy, FDA Says
Pfizer will include FDA’s recommendation that prescribers consider alternative therapy in its promotion to doctors. The company has also agreed to suspend direct-to-consumer advertising for the COX-2 inhibitor following release of trial data showing an increased cardiovascular risk for patients on the drug.
FDA On Celebrex: Use Low Dose, If At All
FDA is advising physicians to consider alternative therapies and lowest effective dose. During a teleconference, FDA’s Crawford says Celebrex and COX-2s may be appropriate for patients who need favorable GI profile compared to older NSAIDs, despite celecoxib product warning on NSAID GI toxicity.